奥氮平与利培酮对精神分裂症患者认知功能的影响

目的：探讨奥氮平与利培酮对精神分裂症患者认知功能的影响。方法将80例精神分裂症患者分为两组。奥氮平组（41例）予以奥氮平治疗，利培酮组（39例）予以利培酮治疗，观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，重复性成套神经心理状态测验评定认知功能，副反应量表评定不良反应。结果治疗2周末起两组阳性与阴性症状量表总分较治疗前显著降低（ P＜0．05或0．01），治疗8周末重复性成套神经心理状态测验总分较治疗前显著升高（P＜0．05或0．01），同期两组各量表评分比较差异均无显著性（P＞0．05）；奥氮平组显效率为48．8％、总有效率为87．8％，利培酮组分别为48．7％、87．2％，两组比较差异无显著性（χ2＝3．05、0．01，P＞0．05）。奥氮平组失眠、肌强直及静坐不能发生率显著低于利培酮组（ P＜0．05）。结论组奥氮平与利培酮治疗精神分裂症疗效显著且相当，均能显著改善患者的认知功能，但奥氮平安全性更高。

Influences of olanzapine and risperidone on cognitive function of schizophrenic

Objective To explore the influences of olanzapine and risperidone on cognitive function of schizophrenic .Methods Eighty schizophrenics were assigned to two groups .Olanzapine group （n=41） was treated with olanzapine and risperidone group （n=39） with risperidone for 8 weeks .Before and after treatment clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） ,cogni-tive functions with the Repeatable Battery for the Assessment of Neuropsychological Status （RBANS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results Since the end of the 2nd week the total score of the PANSS lowered more significantly compared with pre-treatment （P〈0 .05 or 0 .01） ,at the end of the 8th week that of the RBANS heightened （P〈0 .05 or 0 .01） ,and there were no significant group differences in each scale score in the corresponding period （P〉0 .05）;obvious and total effective rate were respectively 48 .8% and 87 .8% in olanzapine and 48 .7% and 87 .2% risperidone group , which showed no notable differences （χ2 =3 .05 ,0 .01 ,P〉0 .05） .The incidence of insomnia ,myotonia and akathisia was significantly lower in olanzapine than risperidone group （P〈0 .05） .Conclusion Olanza-pine has an evident effect on schizophrenia equivalent to risperidone ,both could notably improve patients’ cognitive function ,and olanzapine has higher safety .